Version 1
: Received: 3 August 2022 / Approved: 3 August 2022 / Online: 3 August 2022 (10:22:20 CEST)
How to cite:
Hayashi, T.; Sano, K.; Yaegashi, N.; Konishi, I. Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer. Preprints2022, 2022080081. https://doi.org/10.20944/preprints202208.0081.v1.
Hayashi, T.; Sano, K.; Yaegashi, N.; Konishi, I. Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer. Preprints 2022, 2022080081. https://doi.org/10.20944/preprints202208.0081.v1.
Cite as:
Hayashi, T.; Sano, K.; Yaegashi, N.; Konishi, I. Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer. Preprints2022, 2022080081. https://doi.org/10.20944/preprints202208.0081.v1.
Hayashi, T.; Sano, K.; Yaegashi, N.; Konishi, I. Pathological Evidence for Residual SARS-CoV-2 in the Micrometastatic Niche of a Patient with Ovarian Cancer. Preprints 2022, 2022080081. https://doi.org/10.20944/preprints202208.0081.v1.
Abstract
In previous clinical studies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with cancer has a high risk of aggravation and mortality than in healthy infected individuals. The inoculation with the COVID-19 vaccine reduces the risk of SARS-CoV-2 infection and COVID- 19 severity. However, vaccination-induced production of anti-SARS-CoV-2 antibodies is said to be lower in patients with cancer than in healthy individuals. Additionally, the rationale for why patients with cancer become more severe with COVID-19 is not well understood. Therefore, we examined the infection status of SARS-CoV-2 in primary tumor and micrometastasis tissues of patients with cancer and COVID-19. In this study, angiotensin-converting enzyme 2 (ACE2) expression was observed, and SARS-CoV-2 particles were detected in ovarian tissue cells in contact with the micrometastatic niche of high-grade serous ovarian cancer. We believe that more severe COVID-19 cases in patients with cancer may be attributed to these pathological features.
Keywords
SARS-CoV-2; COVID-19; micrometastatic niche; Patient with Cancer
Subject
LIFE SCIENCES, Virology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
